logo

For the Inventor, By the Inventor

Marlborough, MA, United States of America

Rxi Pharmaceuticals Corporation

Calculating rank
USPTO Granted Patents = 16

% Expired Patents = 12.5


Forward Citations = 656

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Joanne Kamens (15 out of 30 patents)

silverMedal Anastasia Khvorova (15 out of 207 patents)

bronzeMedal Tod M Woolf (14 out of 50 patents)

4.  William Salomon (13 out of 28 patents)

5.  Dmitry Samarsky (11 out of 22 patents)

6.  James Cardia (9 out of 23 patents)

7.  Pamela A Pavco (6 out of 13 patents)

8.  Karen G Bulock (3 out of 8 patents)

9.  Lyn Libertine (3 out of 8 patents)

10.  Michelle Miller (1 out of 2 patents)

11.  William R Levis (4 patents)

12.  Leonard L Kaplan (6 patents)

13.  John G Callahan (1 patent)


16 patents:

1. 10167471 - Inhibition of PCSK9 through RNAI (2019-01-01),
2. 10138485 - Neutral nanotransporters (2018-11-27),
3. 10131904 - Modified RNAi polynucleotides and uses thereof (2018-11-20),
4. 10041073 - Reduced size self-delivering RNAi compounds (2018-08-07),
5. 9963702 - RNA interference in dermal and fibrotic indications (2018-05-08),
6. 9938530 - RNA interference in skin indications (2018-04-10),
7. 9745574 - RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality (2017-08-29),
8. 9493774 - Inhibition of PCSK9 through RNAi (2016-11-15),
9. 9340786 - RNA interference in dermal and fibrotic indications (2016-05-17),
10. 9303259 - RNA interference in skin indications (2016-04-05),
11. 9175289 - Reduced size self-delivering RNAi compounds (2015-11-03),
12. 9095504 - RNA interference in ocular indications (2015-08-04),
13. 9074211 - Inhibition of MAP4K4 through RNAI (2015-07-07),
14. 8815818 - Phagocytic cell delivery of RNAI (2014-08-26),
15. 8796443 - Reduced size self-delivering RNAi compounds (2014-08-05),
Company Overview
Rxi Pharmaceuticals Corporation is a biotechnology company based in Marlborough, Massachusetts, focused on developing innovative therapeutics for the treatment of various diseases. The company specializes in RNA-targeted therapeutics, leveraging its proprietary technology platforms to create novel treatments aimed at addressing unmet medical needs. Rxi's research encompasses a range of therapeutic areas, including dermatology and oncology, positioning it at the forefront of RNA-based drug development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Rxi Pharmaceuticals Corporation USPTO Patent Assignee Logo
16 Patents

#32 in Marlborough, MA

#1,204 in Massachusetts

#19,944 in US

#37,887 in the World

Marlborough, MA (US)
Marlborough, MA, United States of America

Rxi Pharmaceuticals Corporation

Forward Citations = 656

10 inventors:

goldMedal Joanne Kamens (15 out of 30 patents)

silverMedal Anastasia Khvorova (15 out of 207 patents)

bronzeMedal Tod M Woolf (14 out of 50 patents)

4.  William Salomon (13 out of 28 patents)

5.  Dmitry Samarsky (11 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rxi Pharmaceuticals Corporation. Retrieved from https://idiyas.com/company/rxi-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…